Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705674 | 0.92 | DRD2 (0.59) | DRD2DRD4CXCR4ACHE | |
| SCHEMBL8446486 | 0.92 | LTA4H (0.65) | DRD2DRD4CXCR4LTA4HBCHE | |
| SCHEMBL14127744 | 0.90 | DRD2 (0.56) | DRD2DRD4CXCR4LTA4HBCHE | |
| SCHEMBL15054621 | 0.90 | DRD2 (0.56) | DRD2DRD4CXCR4LTA4HBCHE | |
| SCHEMBL28534937 | 0.88 | DRD2 (0.62) | DRD2DRD4CXCR4BCHEACHE | |
| SCHEMBL28534938 | 0.86 | DRD2 (0.61) | DRD2DRD4CXCR4ACHECCR3 | |
| SCHEMBL8809184 | 0.86 | DRD2 (0.61) | DRD2DRD4CXCR4BCHEACHE | |
| Hydrochloric Acid SCHEMBL9536536 | 0.85 | DRD2 (0.60) | DRD2DRD4CXCR4BCHEACHE | |
| SCHEMBL31050638 | 0.85 | DRD2 (0.51) | DRD2DRD4LTA4HBCHEACHE | |
| SCHEMBL4505679 | 0.84 | ACHE (0.63) | CXCR4BCHEACHECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2920173-B1 | TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2920173-B1 | TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20150274734-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-20150274734-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| WO-2014062548-A1 | TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014062548-A1 | TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | WO | disclosed |
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| EP-1730137-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | Bristol-Myers Squibb Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095383-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, BDKRB2 | DRD2 3079/4885DRD4 4521/4885CXCR4 471/4885 |
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | DRD2 1526/4885DRD4 3689/4885CXCR4 241/4885 |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | CALCRL, CALCR, CALCA | DRD2 2821/4885DRD4 4305/4885CXCR4 253/4885 |
| US-20150274734-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB2, CALCR | DRD2 1801/4885DRD4 4106/4885CXCR4 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.